First, we analyzed the clinical outcome of patients with gliomas harboring low or high expression of TREM1 by using the R2: Genomic Analysis and Visualization Platform (http://r2.amc.nl) Madhavan—550 MAS.5.0-u133p2 study; low expression levels of TREM1 were associated with favorable outcome (Figure 1A). The gene discussed is TREM1; the disease is central nervous system cancer.